UNSPSC 51102874: Sulfabenzamide/sulfacetamide/sulfathiazole/urea

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.

UNSPSC 51102874 Sulfabenzamide/sulfacetamide/sulfathiazole/urea is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal pharmaceutical scope. The code's product class—a combination topical sulfonamide antimicrobial agent—appears infrequently in posted state and local opportunities, and the recent activity tagged under this code does not reflect purchases of the specified compound. Instead, state and local buyers posting pharmaceutical procurement notices tend to solicit through broader pharmaceutical supply and warehouse contracts that encompass multiple drug products and formulations, with issuing bodies including state health departments and county community health systems using cooperative purchasing vehicles such as MMCAP and competitive sealed-bid processes.

Geographic activity is sparse and scattered. The Illinois Department of Public Health posted a piggyback pharmaceutical warehouse award through MMCAP Infuse on August 28, 2026, for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), totaling $2,999,999.11 over a three-year term awarded to Chartwell Rx LLC; a separate Seminole County, Florida procurement issued via IFB in June 2026 sought Naloxone and drug deactivation systems with quarterly delivery requirements. Neither opportunity directly reflects demand for the sulfabenzamide/sulfacetamide compound specified in the code. The code shows little relevant recent activity and does not present a clear signal of material state and local demand for this particular pharmaceutical formulation.